Press Releases

Date Title and Summary Additional Formats
Toggle Summary NewLink Genetics Appoints Chad A. Johnson to Board of Directors
AMES, Iowa, March 21, 2018 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (NASDAQ:NLNK) today announced the appointment of Chad A. Johnson, 39, to the Company's Board of Directors.  In connection with this appointment, the Company's Board expanded from seven directors to eight.
View HTML
Toggle Summary NewLink Genetics Announces Presentation of Abstracts at AACR Annual Meeting
AMES, Iowa , March 14, 2018 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (NASDAQ:NLNK) today reported that two abstracts pertaining to the company's indoximod program will be presented at the American Association for Cancer Research (AACR) 2018 Annual Meeting in Chicago.
View HTML
Toggle Summary NewLink Genetics to Participate in Upcoming Investor Conferences
AMES, Iowa , March 12, 2018 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (NASDAQ:NLNK) announced today that the company will participate in the following investor conferences: Oppenheimer 28 th Annual Healthcare Conference, March 20, 2018 in New York City   8th Annual Cancer Immunotherapy
View HTML
Toggle Summary NewLink Genetics Reports Fourth Quarter, Year-End 2017 Financial Results and Provides Update for Indoximod Programs
Management to Host Conference Call Today at 4:30 p.m. ET AMES, Iowa , March 01, 2018 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (NASDAQ:NLNK) today reported consolidated financial results for the fourth quarter and year ended 2017, as well as progress in its clinical development programs. The
View HTML
Toggle Summary NewLink Genetics to Host Its Fourth Quarter and Year End 2017 Financial Results Conference Call on March 1, 2018
AMES, Iowa , Feb. 16, 2018 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (NASDAQ:NLNK) today announced that it will release its fourth quarter and year end 2017 financial results on Thursday, March 1 , 2018.  The company has scheduled a conference call for 4:30 PM ET the same day to discuss the
View HTML
Toggle Summary NewLink Genetics to Participate in Upcoming Investor Conferences
AMES, Iowa , Feb. 06, 2018 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation  (NASDAQ:NLNK) announced today that the company will participate in the following investor conferences: BIO CEO & Investor Conference, February 12, 2018 , in New York City SunTrust Robinson Humphrey 4 th Annual Orphan Drug
View HTML
Toggle Summary NewLink Genetics Outlines 2018 Business Priorities to Support Phase 3 Pivotal Trial of Indoximod Plus PD-1 Inhibitors
NewLink Genetics updates financial and clinical guidance
View HTML
Toggle Summary NewLink Genetics to Present at the 36th Annual J.P. Morgan Healthcare Conference
AMES, Iowa , Dec. 21, 2017 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation  (NASDAQ:NLNK) announced today that the company will present at the 36 th Annual J.P. Morgan Healthcare Conference on Thursday, January 11, 2018 , at 11:00am PT / 2:00pm ET in San Francisco , CA.  A live webcast of the
View HTML
Toggle Summary NewLink Genetics to Participate in Upcoming Investor Conference
AMES, Iowa , Nov. 27, 2017 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (NASDAQ:NLNK) will participate in the Global Mizuho Investor Conference on Tuesday, December 5 th , in New York City.  The format of the conference is one-on-one meetings with investors only.  About NewLink Genetics
View HTML
Toggle Summary NewLink Genetics Announces the Presentation of Indoximod Data in Phase 1 Study for Children
AMES, Iowa , Nov. 20, 2017 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (NASDAQ:NLNK) today announced the presentation of data from a Phase 1 study of indoximod, in combination with radiation, for children with progressive brain tumors.  These data were presented at the Society for
View HTML